{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T22:42:01Z","timestamp":1789771321831,"version":"4.0.1"},"reference-count":209,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2020,8,24]],"date-time":"2020-08-24T00:00:00Z","timestamp":1598227200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,11,15]]},"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Several targeted therapies for cancer have been associated with cardiovascular toxicity. The evidence for this association has not been synthesized systematically nor has the quality of evidence been considered. We synthesized systematic review evidence of cardiovascular toxicity of individual targeted agents.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n We searched MEDLINE, Embase, and the Cochrane Database of Systematic Reviews for systematic reviews with meta-analyses of cardiovascular outcomes for individual agents published to May 2020. We selected reviews according to prespecified eligibility criteria (International Prospective Register of Systematic Reviews CRD42017080014). We classified evidence of cardiovascular toxicity as sufficient, probable, possible, or indeterminate for specific cardiovascular outcomes based on statistical significance, study quality, and size.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n From 113 systematic reviews, we found at least probable systematic review evidence of cardiovascular toxicity for 18 agents, including high- and all-grade hypertension for bevacizumab, ramucirumab, axitinib, cediranib, pazopanib, sorafenib, sunitinib, vandetanib, aflibercept, abiraterone, and enzalutamide, and all-grade hypertension for nintedanib; high- and all-grade arterial thromboembolism (includes cardiac and\/or cerebral events) for bevacizumab and abiraterone, high-grade arterial thromboembolism for trastuzumab, and all-grade arterial thromboembolism for sorafenib and tamoxifen; high- and all-grade venous thromboembolism (VTE) for lenalidomide and thalidomide, high-grade VTE for cetuximab and panitumumab, and all-grade VTE for bevacizumab; high- and all-grade left ventricular ejection fraction decline or congestive heart failure for bevacizumab and trastuzumab, and all-grade left ventricular ejection fraction decline\/congestive heart failure for pazopanib and sunitinib; and all-grade corrected QT interval prolongation for vandetanib.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Our review provides an accessible summary of the cardiovascular toxicity of targeted therapy to assist clinicians and patients when managing cardiovascular health.<\/jats:p>\n <\/jats:sec>","DOI":"10.1093\/jncics\/pkaa076","type":"journal-article","created":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T07:42:53Z","timestamp":1597822973000},"source":"Crossref","is-referenced-by-count":46,"title":["Cardiovascular Toxicity of Targeted Therapies for Cancer: An Overview of Systematic Reviews"],"prefix":"10.1093","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1570-2852","authenticated-orcid":false,"given":"Marina T","family":"Van Leeuwen","sequence":"first","affiliation":[{"name":"Centre for Big Data Research in Health, University of New South Wales, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Luu","sequence":"additional","affiliation":[{"name":"Centre for Big Data Research in Health, University of New South Wales, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Gurney","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health Sciences, Macquarie University, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin R","family":"Brown","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health Sciences, Macquarie University, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sallie-Anne","family":"Pearson","sequence":"additional","affiliation":[{"name":"Centre for Big Data Research in Health, University of New South Wales, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Webber","sequence":"additional","affiliation":[{"name":"Department of Oncology, Monash Health, Clayton, Victoria, Australia"},{"name":"School of Clinical Sciences, Monash University, Clayton, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Hunt","sequence":"additional","affiliation":[{"name":"Cancer Voices NSW, Milsons Point, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4350-2794","authenticated-orcid":false,"given":"Soojung","family":"Hong","sequence":"additional","affiliation":[{"name":"Centre for Big Data Research in Health, University of New South Wales, Sydney, New South Wales, Australia"},{"name":"Division of Oncology-Haematology, Department of Internal Medicine, National Health Insurance Service Ilsan Hospital, Goyang, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey P","family":"Delaney","sequence":"additional","affiliation":[{"name":"Liverpool Cancer Therapy Centre, Liverpool, New South Wales, Australia"},{"name":"Collaboration for Cancer Outcomes Research and Evaluation, Ingham Institute for Applied Medical Research, Liverpool, New South Wales, Australia"},{"name":"South Western Sydney Clinical School, University of New South Wales, Liverpool, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3612-8298","authenticated-orcid":false,"given":"Claire M","family":"Vajdic","sequence":"additional","affiliation":[{"name":"Centre for Big Data Research in Health, University of New South Wales, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,8,24]]},"reference":[{"issue":"10","key":"2020122808494592700_pkaa076-B1","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.jacc.2015.07.025","article-title":"Vascular and metabolic implications of\u00a0novel targeted cancer therapies: focus on kinase inhibitors","volume":"66","author":"Li","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2020122808494592700_pkaa076-B2","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ijcard.2019.01.038","article-title":"Cardio-oncology\u2014strategies for management of cancer-therapy related cardiovascular disease","volume":"280","author":"Totzeck","year":"2019","journal-title":"Int J Cardiol"},{"issue":"9","key":"2020122808494592700_pkaa076-B3","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1001\/jamacardio.2016.2132","article-title":"Oncocardiology\u2014past, present, and future: a review","volume":"1","author":"Yeh","year":"2016","journal-title":"JAMA Cardiol"},{"key":"2020122808494592700_pkaa076-B4","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [Updated March 2011]","author":"Becker","year":"2011"},{"issue":"3","key":"2020122808494592700_pkaa076-B5","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/XEB.0000000000000055","article-title":"Summarizing systematic reviews: methodological development, conduct and reporting of an umbrella review approach","volume":"13","author":"Aromataris","year":"2015","journal-title":"Int J Evid Based Healthc"},{"issue":"20","key":"2020122808494592700_pkaa076-B6","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1136\/bjsports-2017-097621","article-title":"Next-generation systematic reviews: prospective meta-analysis, individual-level data, networks and umbrella reviews","volume":"51","author":"Ioannidis","year":"2017","journal-title":"Br J Sports Med"},{"key":"2020122808494592700_pkaa076-B7","first-page":"e021064","article-title":"Cardiovascular toxicity of targeted therapies for cancer: a protocol for an overview of systematic reviews","volume-title":"BMJ Open","author":"van Leeuwen","year":"2018"},{"issue":"1","key":"2020122808494592700_pkaa076-B8","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/2046-4053-1-2","article-title":"The nuts and bolts of PROSPERO: an international prospective register of systematic reviews","volume":"1","author":"Booth","year":"2012","journal-title":"Syst Rev"},{"issue":"9760","key":"2020122808494592700_pkaa076-B9","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/S0140-6736(10)60903-8","article-title":"An international registry of systematic-review protocols","volume":"377","author":"Booth","year":"2011","journal-title":"Lancet"},{"key":"2020122808494592700_pkaa076-B10","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"2020122808494592700_pkaa076-B11","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"2020122808494592700_pkaa076-B12","article-title":"BMJ best practice: study design search filters","author":"BMJ Publishing Group"},{"issue":"1","key":"2020122808494592700_pkaa076-B13","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/s12874-019-0855-0","article-title":"Definition of a systematic review used in overviews of systematic reviews, meta-epidemiological studies and textbooks","volume":"19","author":"Krnic Martinic","year":"2019","journal-title":"BMC Med Res Methodol"},{"key":"2020122808494592700_pkaa076-B14","author":"WHO Collaborating Centre for Drug Statistics Methodology"},{"issue":"1","key":"2020122808494592700_pkaa076-B15","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1471-2288-7-10","article-title":"Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews","volume":"7","author":"Shea","year":"2007","journal-title":"BMC Med Res Methodol"},{"issue":"10","key":"2020122808494592700_pkaa076-B16","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.jclinepi.2008.10.009","article-title":"AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews","volume":"62","author":"Shea","year":"2009","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"2020122808494592700_pkaa076-B17","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jclinepi.2014.12.009","article-title":"Systematic review found AMSTAR, but not R(evised)-AMSTAR, to have good measurement properties","volume":"68","author":"Pieper","year":"2015","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"2020122808494592700_pkaa076-B18","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/jrsm.1229","article-title":"Risk of bias in overviews of reviews: a scoping review of methodological guidance and four-item checklist","volume":"8","author":"Ballard","year":"2017","journal-title":"Res Syn Meth"},{"issue":"1","key":"2020122808494592700_pkaa076-B19","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13643-017-0534-3","article-title":"Selecting and implementing overview methods: implications from five exemplar overviews","volume":"6","author":"Pollock","year":"2017","journal-title":"Syst Rev"},{"issue":"12","key":"2020122808494592700_pkaa076-B20","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.jclinepi.2012.06.015","article-title":"Overviews of reviews often have limited rigor: a systematic review","volume":"65","author":"Pieper","year":"2012","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"2020122808494592700_pkaa076-B21","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s10654-019-00576-5","article-title":"A 24-step guide on how to design, conduct, and successfully publish a systematic review and meta-analysis in medical research","volume":"35","author":"Muka","year":"2020","journal-title":"Eur J Epidemiol"},{"key":"2020122808494592700_pkaa076-B22","author":"International Agency for Research on Cancer"},{"issue":"3","key":"2020122808494592700_pkaa076-B23","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S1474-4422(14)70267-4","article-title":"Environmental risk factors and multiple sclerosis: an umbrella review of systematic reviews and meta-analyses","volume":"14","author":"Belbasis","year":"2015","journal-title":"Lancet Neurol"},{"key":"2020122808494592700_pkaa076-B24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.parkreldis.2015.12.008","article-title":"Environmental risk factors and Parkinson\u2019s disease: an umbrella review of meta-analyses","volume":"23","author":"Bellou","year":"2016","journal-title":"Parkinsonism Relat Disord"},{"issue":"3","key":"2020122808494592700_pkaa076-B25","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1136\/ebmental-2018-300014","article-title":"Ten simple rules for conducting umbrella reviews","volume":"21","author":"Fusar-Poli","year":"2018","journal-title":"Evid Based Mental Health"},{"key":"2020122808494592700_pkaa076-B26","author":"McIlwain","year":"2013"},{"issue":"3","key":"2020122808494592700_pkaa076-B27","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.critrevonc.2014.06.003","article-title":"Risk of cardiovascular toxicities in patients with solid tumors treated with sunitinib, axitinib, cediranib or regorafenib: an updated systematic review and comparative meta-analysis","volume":"92","author":"Abdel-Rahman","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"2020122808494592700_pkaa076-B28","first-page":"221","article-title":"Thromboembolic events associated with bevacizumab plus chemotherapy for patients with colorectal cancer: a meta-analysis of randomized controlled trials","volume":"9","author":"Alahmari","year":"2016","journal-title":"Am Health Drug Benefits"},{"issue":"11","key":"2020122808494592700_pkaa076-B29","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s40261-013-0125-6","article-title":"Safety of bevacizumab in treating metastatic colorectal cancer: a systematic review and meta-analysis of all randomized clinical trials","volume":"33","author":"Dai","year":"2013","journal-title":"Clin Drug Investig"},{"issue":"12","key":"2020122808494592700_pkaa076-B30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12032-014-0340-x","article-title":"Is it safe to give anthracyclines concurrently with trastuzumab in neo-adjuvant or metastatic settings for HER2-positive breast cancer? A meta-analysis of randomized controlled trials","volume":"31","author":"Du","year":"2014","journal-title":"Med Oncol"},{"issue":"11","key":"2020122808494592700_pkaa076-B31","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1634\/theoncologist.2009-0155","article-title":"Safety of bevacizumab in patients with advanced cancer: a meta-analysis of randomized controlled trials","volume":"15","author":"Geiger-Gritsch","year":"2010","journal-title":"Oncologist"},{"issue":"5","key":"2020122808494592700_pkaa076-B32","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.ctrv.2008.02.003","article-title":"A meta-analysis and systematic review of thalidomide for patients with previously untreated multiple myeloma","volume":"34","author":"Hicks","year":"2008","journal-title":"Cancer Treat Rev"},{"issue":"12","key":"2020122808494592700_pkaa076-B33","doi-asserted-by":"crossref","first-page":"11741","DOI":"10.1007\/s13277-014-2227-z","article-title":"Efficacy and toxicity of adding cetuximab to chemotherapy in the treatment of metastatic colorectal cancer: a meta-analysis from 12 randomized controlled trials","volume":"35","author":"Lv","year":"2014","journal-title":"Tumor Biol"},{"issue":"12","key":"2020122808494592700_pkaa076-B34","doi-asserted-by":"crossref","first-page":"e112530","DOI":"10.1371\/journal.pone.0112530","article-title":"An updated meta-analysis of randomized controlled trials assessing the effect of sorafenib in advanced hepatocellular carcinoma","volume":"9","author":"Peng","year":"2014","journal-title":"PLoS One"},{"issue":"3","key":"2020122808494592700_pkaa076-B35","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/bcp.12149","article-title":"Incidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis","volume":"76","author":"Qi","year":"2013","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"2020122808494592700_pkaa076-B36","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00280-012-2025-5","article-title":"Incidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysis","volume":"71","author":"Qi","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"2020122808494592700_pkaa076-B37","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/j.1365-2125.2012.04417.x","article-title":"Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials","volume":"75","author":"Qi","year":"2013","journal-title":"Br J Clin Pharmacol"},{"issue":"25","key":"2020122808494592700_pkaa076-B38","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1200\/JCO.2010.34.4309","article-title":"Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib","volume":"29","author":"Richards","year":"2011","journal-title":"J Clin Oncol"},{"issue":"3","key":"2020122808494592700_pkaa076-B39","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s10549-012-2189-z","article-title":"Lapatinib, trastuzumab or the combination added to preoperative chemotherapy for breast cancer: a meta-analysis of randomized evidence","volume":"135","author":"Valachis","year":"2012","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"2020122808494592700_pkaa076-B40","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv342","article-title":"Maintenance therapy with immunomodulatory drugs in multiple myeloma: a meta-analysis and systematic review","volume":"108","author":"Wang","year":"2016","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"2020122808494592700_pkaa076-B41","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1470-2045(08)70003-2","article-title":"Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis","volume":"9","author":"Wu","year":"2008","journal-title":"Lancet Oncol"},{"issue":"7","key":"2020122808494592700_pkaa076-B42","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1097\/CAD.0b013e32835514f4","article-title":"Addition of vandetanib to chemotherapy in advanced solid cancers: a meta-analysis","volume":"23","author":"Wu","year":"2012","journal-title":"Anticancer Drugs"},{"issue":"17","key":"2020122808494592700_pkaa076-B43","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.3760\/cma.j.issn.0366-6999.20122920","article-title":"Chemotherapy with or without gefitinib in patients with advanced non-small-cell lung cancer: a meta-analysis of 6844 patients","volume":"126","author":"Zhou","year":"2013","journal-title":"Chin Med J"},{"issue":"1","key":"2020122808494592700_pkaa076-B44","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/02841860802314720","article-title":"Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis","volume":"48","author":"Zhu","year":"2009","journal-title":"Acta Oncol"},{"issue":"06","key":"2020122808494592700_pkaa076-B45","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1160\/TH06-09-0494","article-title":"Thalidomide and thrombosis\u2014a meta-analysis","volume":"97","author":"El Accaoui","year":"2007","journal-title":"Thromb Haemost"},{"issue":"8","key":"2020122808494592700_pkaa076-B46","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/ajh.22076","article-title":"High-dose imatinib for newly diagnosed chronic phase chronic myeloid leukemia patients-systematic review and meta-analysis","volume":"86","author":"Gafter-Gvili","year":"2011","journal-title":"Am J Hematol"},{"issue":"1","key":"2020122808494592700_pkaa076-B47","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1186\/s12885-018-5040-z","article-title":"Cetuximab for esophageal cancer: an updated meta-analysis of randomized controlled trials","volume":"18","author":"Huang","year":"2018","journal-title":"BMC Cancer"},{"key":"2020122808494592700_pkaa076-B48","first-page":"2421","article-title":"Risk of adverse events with bevacizumab addition to therapy in advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials","volume":"9","author":"Lai","year":"2016","journal-title":"Onco Targets Ther"},{"issue":"5","key":"2020122808494592700_pkaa076-B49","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1634\/theoncologist.2015-0424","article-title":"Risk of congestive heart failure in early breast cancer patients undergoing adjuvant treatment with trastuzumab: a meta-analysis","volume":"21","author":"Long","year":"2016","journal-title":"Oncologist"},{"issue":"1","key":"2020122808494592700_pkaa076-B50","doi-asserted-by":"crossref","DOI":"10.1186\/s40885-019-0116-x","article-title":"Risk of hypertension in cancer patients treated with abiraterone: a meta-analysis","volume":"25","author":"Zhu","year":"2019","journal-title":"Clin Hypertens"},{"issue":"1","key":"2020122808494592700_pkaa076-B51","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/jnci\/djx141","article-title":"Toxicity of extended adjuvant therapy with aromatase inhibitors in early breast cancer: a systematic review and meta-analysis","volume":"110","author":"Goldvaser","year":"2018","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"2020122808494592700_pkaa076-B52","doi-asserted-by":"crossref","first-page":"13221","DOI":"10.18632\/oncotarget.6507","article-title":"Efficacy and toxicity of bevacizumab in recurrent ovarian disease: an update meta-analysis on phase III trials","volume":"7","author":"Marchetti","year":"2016","journal-title":"Oncotarget"},{"issue":"2","key":"2020122808494592700_pkaa076-B53","doi-asserted-by":"crossref","first-page":"775","DOI":"10.4103\/0973-1482.148700","article-title":"Incidence and risk of hypertension associated with ramucirumab in cancer patients: a systematic review and meta-analysis","volume":"12","author":"Qi","year":"2016","journal-title":"J Can Res Ther"},{"issue":"2","key":"2020122808494592700_pkaa076-B54","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00228-013-1598-1","article-title":"Risk of hypertension with regorafenib in cancer patients: a systematic review and meta-analysis","volume":"70","author":"Wang","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"key":"2020122808494592700_pkaa076-B55","doi-asserted-by":"crossref","first-page":"6405","DOI":"10.2147\/OTT.S156760","article-title":"Adverse events risk associated with regorafenib in the treatment of advanced solid tumors: meta-analysis of randomized controlled trials","volume":"11","author":"Yin","year":"2018","journal-title":"Onco Targets Ther"},{"issue":"2","key":"2020122808494592700_pkaa076-B56","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.critrevonc.2014.12.008","article-title":"Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors","volume":"94","author":"Ghatalia","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"issue":"5","key":"2020122808494592700_pkaa076-B57","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1463-1318.2009.01916.x","article-title":"Cetuximab-based therapy vs noncetuximab therapy in advanced or metastatic colorectal cancer: a meta-analysis of seven randomized controlled trials","volume":"12","author":"Liu","year":"2010","journal-title":"Colorectal Dis"},{"issue":"9","key":"2020122808494592700_pkaa076-B58","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.4103\/0366-6999.156134","article-title":"Efficacy and safety of lenalidomide in the treatment of multiple myeloma: a systematic review and meta-analysis of randomized controlled trials","volume":"128","author":"Qiao","year":"2015","journal-title":"Chin Med J"},{"issue":"9","key":"2020122808494592700_pkaa076-B59","first-page":"720","article-title":"Effect of pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer: a meta-analysis","volume":"55","author":"Tian","year":"2017","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"12","key":"2020122808494592700_pkaa076-B60","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.2217\/fon.14.42","article-title":"Risk of cardiovascular toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysis","volume":"10","author":"Abdel-Rahman","year":"2014","journal-title":"Future Oncol"},{"issue":"13","key":"2020122808494592700_pkaa076-B61","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1200\/JCO.2009.27.2757","article-title":"Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials","volume":"28","author":"Choueiri","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"2020122808494592700_pkaa076-B62","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1756-9966-30-54","article-title":"Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: meta-regression analysis of randomized trials","volume":"30","author":"Cuppone","year":"2011","journal-title":"J Exp Clin Cancer Res"},{"issue":"10","key":"2020122808494592700_pkaa076-B63","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/jhh.2013.30","article-title":"Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis","volume":"27","author":"Funakoshi","year":"2013","journal-title":"J Hum Hypertens"},{"issue":"1","key":"2020122808494592700_pkaa076-B64","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1756-9966-29-58","article-title":"Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials","volume":"29","author":"Loupakis","year":"2010","journal-title":"J Exp Clin Cancer Res"},{"issue":"48","key":"2020122808494592700_pkaa076-B65","doi-asserted-by":"crossref","first-page":"84572","DOI":"10.18632\/oncotarget.20028","article-title":"Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials","volume":"8","author":"Moreira","year":"2017","journal-title":"Oncotarget"},{"issue":"2","key":"2020122808494592700_pkaa076-B66","doi-asserted-by":"crossref","first-page":"691","DOI":"10.7314\/APJCP.2013.14.2.691","article-title":"Meta-analysis of the efficacy of sorafenib for hepatocellular carcinoma","volume":"14","author":"Wang","year":"2013","journal-title":"Asian Pac J Cancer Prev"},{"issue":"3","key":"2020122808494592700_pkaa076-B67","doi-asserted-by":"crossref","first-page":"538","DOI":"10.3760\/cma.j.issn.0366-6999.20132241","article-title":"Efficacy and safety of first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a meta-analysis","volume":"127","author":"Wang","year":"2014","journal-title":"Chin Med J"},{"issue":"4","key":"2020122808494592700_pkaa076-B68","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s40261-015-0272-z","article-title":"Incidence and risk of hypertension with ramucirumab in cancer patients: a meta-analysis of published studies","volume":"35","author":"Wang","year":"2015","journal-title":"Clin Drug Investig"},{"issue":"3","key":"2020122808494592700_pkaa076-B69","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s12072-015-9700-7","article-title":"Sorafenib combined with transarterial chemoembolization in patients with hepatocellular carcinoma: a meta-analysis and systematic review","volume":"10","author":"Wang","year":"2016","journal-title":"Hepatol Int"},{"issue":"6","key":"2020122808494592700_pkaa076-B70","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.clinre.2016.04.006","article-title":"Efficacy and safety of transarterial chemoembolization plus sorafenib for early or intermediate stage hepatocellular carcinoma: a systematic review and meta-analysis of randomized controlled trials","volume":"40","author":"Zeng","year":"2016","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"5","key":"2020122808494592700_pkaa076-B71","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S1499-3872(12)60209-4","article-title":"Sorafenib in treatment of patients with advanced hepatocellular carcinoma: a systematic review","volume":"11","author":"Zhang","year":"2012","journal-title":"Hepatobiliary Pancreat Dis Int"},{"issue":"6","key":"2020122808494592700_pkaa076-B72","doi-asserted-by":"crossref","first-page":"e100305","DOI":"10.1371\/journal.pone.0100305","article-title":"Transarterial chemoembolization (TACE) plus sorafenib versus TACE for intermediate or advanced stage hepatocellular carcinoma: a meta-analysis","volume":"9","author":"Zhang","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"2020122808494592700_pkaa076-B73","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1080\/14737140.2018.1419871","article-title":"Toxicity profile characteristics of novel androgen-deprivation therapy agents in patients with prostate cancer: a meta-analysis","volume":"18","author":"Zhu","year":"2018","journal-title":"Exp Rev Anticancer Ther"},{"issue":"8","key":"2020122808494592700_pkaa076-B74","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1007\/s12094-015-1438-0","article-title":"Doublet BRAF\/MEK inhibition versus single-agent BRAF inhibition in the management of BRAF-mutant advanced melanoma, biological rationale and meta-analysis of published data","volume":"18","author":"Abdel-Rahman","year":"2016","journal-title":"Clin Transl Oncol"},{"issue":"9","key":"2020122808494592700_pkaa076-B75","doi-asserted-by":"crossref","first-page":"e0136324","DOI":"10.1371\/journal.pone.0136324","article-title":"Efficacy and safety assessment of the addition of bevacizumab to adjuvant therapy agents in cancer patients: a systematic review and meta-analysis of randomized controlled trials","volume":"10","author":"Ahmadizar","year":"2015","journal-title":"PLoS One"},{"issue":"7","key":"2020122808494592700_pkaa076-B76","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.ctrv.2013.03.004","article-title":"Fulvestrant for advanced breast cancer: a meta-analysis","volume":"39","author":"Al-Mubarak","year":"2013","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"2020122808494592700_pkaa076-B77","doi-asserted-by":"crossref","first-page":"e51780","DOI":"10.1371\/journal.pone.0051780","article-title":"The impact of bevacizumab (Avastin) on survival in metastatic solid tumors--a meta-analysis and systematic review","volume":"8","author":"Amit","year":"2013","journal-title":"PLoS One"},{"issue":"8","key":"2020122808494592700_pkaa076-B78","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s00228-010-0815-4","article-title":"Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: an updated meta-analysis","volume":"66","author":"An","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"key":"2020122808494592700_pkaa076-B79","first-page":"CD006242","article-title":"Trastuzumab-containing regimens for metastatic breast cancer","volume":"6","author":"Balduzzi","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"2020122808494592700_pkaa076-B80","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.lungcan.2011.01.028","article-title":"Efficacy of bevacizumab (Bev) plus chemotherapy (CT) compared to CT alone in previously untreated locally advanced or metastatic non-small cell lung cancer (NSCLC): systematic review and meta-analysis","volume":"74","author":"Botrel","year":"2011","journal-title":"Lung Cancer"},{"key":"2020122808494592700_pkaa076-B81","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2147\/CE.S50474","article-title":"Lapatinib plus chemotherapy or endocrine therapy (CET) versus CET alone in the treatment of HER-2-overexpressing locally advanced or metastatic breast cancer: systematic review and meta-analysis","volume":"8","author":"Botrel","year":"2013","journal-title":"Core Evid"},{"issue":"1","key":"2020122808494592700_pkaa076-B82","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-016-2734-y","article-title":"Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: a systematic review and meta-analysis","volume":"16","author":"Botrel","year":"2016","journal-title":"BMC Cancer"},{"issue":"11","key":"2020122808494592700_pkaa076-B83","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1046\/j.1525-1497.2003.20724.x","article-title":"Meta-analysis of vascular and neoplastic events associated with tamoxifen","volume":"18","author":"Braithwaite","year":"2003","journal-title":"J Gen Intern Med"},{"issue":"19","key":"2020122808494592700_pkaa076-B84","doi-asserted-by":"crossref","first-page":"31318","DOI":"10.18632\/oncotarget.15454","article-title":"Autologous transplantation of cytokine-induced killer cells as an adjuvant therapy for hepatocellular carcinoma in Asia: an update meta-analysis and systematic review","volume":"8","author":"Cai","year":"2017","journal-title":"Oncotarget"},{"issue":"6","key":"2020122808494592700_pkaa076-B85","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s00384-009-0655-9","article-title":"A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer","volume":"24","author":"Cao","year":"2009","journal-title":"Int J Colorectal Dis"},{"issue":"2","key":"2020122808494592700_pkaa076-B86","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3109\/0284186X.2011.631579","article-title":"Risk profile of bevacizumab in patients with non-small cell lung cancer: a meta-analysis of randomized controlled trials","volume":"51","author":"Cao","year":"2012","journal-title":"Acta Oncol"},{"issue":"4","key":"2020122808494592700_pkaa076-B87","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.ctrv.2010.09.001","article-title":"Risk of cardiac dysfunction with trastuzumab in breast cancer patients: a meta-analysis","volume":"37","author":"Chen","year":"2011","journal-title":"Cancer Treatment Rev"},{"issue":"6","key":"2020122808494592700_pkaa076-B88","doi-asserted-by":"crossref","first-page":"e66721","DOI":"10.1371\/journal.pone.0066721","article-title":"Angiogenesis inhibitor bevacizumab increases the risk of ischemic heart disease associated with chemotherapy: a meta-analysis","volume":"8","author":"Chen","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"2020122808494592700_pkaa076-B89","doi-asserted-by":"crossref","first-page":"61","DOI":"10.4048\/jbc.2014.17.1.61","article-title":"Efficacy and safety profile of combining sorafenib with chemotherapy in patients with HER2-negative advanced breast cancer: a meta-analysis","volume":"17","author":"Chen","year":"2014","journal-title":"J Breast Cancer"},{"issue":"5","key":"2020122808494592700_pkaa076-B90","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.3892\/etm.2016.3095","article-title":"Efficacy, safety and administration timing of trastuzumab in human epidermal growth factor receptor 2 positive breast cancer patients: a meta-analysis","volume":"11","author":"Chen","year":"2016","journal-title":"Exp Ther Med"},{"key":"2020122808494592700_pkaa076-B91","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.2147\/OTT.S106055","article-title":"The efficiency and safety of trastuzumab and lapatinib added to neoadjuvant chemotherapy in Her2-positive breast cancer patients: a randomized meta-analysis","volume":"9","author":"Chen","year":"2016","journal-title":"Onco Targets Ther"},{"issue":"6","key":"2020122808494592700_pkaa076-B92","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1200\/JCO.2010.31.9129","article-title":"Congestive heart failure risk in patients with breast cancer treated with bevacizumab","volume":"29","author":"Choueiri","year":"2011","journal-title":"J Clin Oncol"},{"issue":"5","key":"2020122808494592700_pkaa076-B93","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1093\/annonc\/mdr432","article-title":"Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis","volume":"23","author":"Cortes","year":"2012","journal-title":"Ann Oncol"},{"issue":"6","key":"2020122808494592700_pkaa076-B94","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s40259-018-0322-1","article-title":"Comparative effectiveness and safety of monoclonal antibodies (bevacizumab, cetuximab, and panitumumab) in combination with chemotherapy for metastatic colorectal cancer: a systematic review and meta-analysis","volume":"32","author":"da Silva","year":"2018","journal-title":"Biodrugs"},{"issue":"6","key":"2020122808494592700_pkaa076-B95","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1634\/theoncologist.2008-0001","article-title":"Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials","volume":"13","author":"Dahabreh","year":"2008","journal-title":"Oncologist"},{"issue":"9","key":"2020122808494592700_pkaa076-B96","doi-asserted-by":"crossref","first-page":"4057","DOI":"10.1007\/s00520-016-3310-3","article-title":"Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents","volume":"24","author":"Escalante","year":"2016","journal-title":"Support Care Cancer"},{"issue":"3","key":"2020122808494592700_pkaa076-B97","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1007\/s13277-014-2799-7","article-title":"The efficacy and safety of bevacizumab combined with chemotherapy in treatment of HER2-negative metastatic breast cancer: a meta-analysis based on published phase III trials","volume":"36","author":"Fang","year":"2015","journal-title":"Tumor Biol"},{"issue":"8","key":"2020122808494592700_pkaa076-B98","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s00432-014-1684-5","article-title":"Sorafenib enhances effects of transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis","volume":"140","author":"Fu","year":"2014","journal-title":"J Cancer Res Clin Oncol"},{"key":"2020122808494592700_pkaa076-B99","first-page":"CD007930","article-title":"Angiogenesis inhibitors for the treatment of ovarian cancer","volume":"9","author":"Gaitskell","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"2020122808494592700_pkaa076-B100","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.dld.2010.10.010","article-title":"Risk\/benefit profile of bevacizumab in metastatic colon cancer: a systematic review and meta-analysis","volume":"43","author":"Galfrascoli","year":"2011","journal-title":"Dig Liver Dis"},{"issue":"8","key":"2020122808494592700_pkaa076-B101","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1080\/17512433.2019.1637252","article-title":"Adjuvant trastuzumab regimen for HER2-positive early-stage breast cancer: a systematic review and meta-analysis","volume":"12","author":"Genuino","year":"2019","journal-title":"Exp Rev Clin Pharmacol"},{"issue":"2","key":"2020122808494592700_pkaa076-B102","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/bjc.2014.564","article-title":"QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors","volume":"112","author":"Ghatalia","year":"2015","journal-title":"Br J Cancer"},{"issue":"18","key":"2020122808494592700_pkaa076-B103","doi-asserted-by":"crossref","first-page":"14619","DOI":"10.18632\/oncotarget.23657","article-title":"The efficacy and safety of paclitaxel and carboplatin with versus without bevacizumab in patients with non-small-cell lung cancer: a systematic review and meta-analysis","volume":"9","author":"Han","year":"2018","journal-title":"Oncotarget"},{"issue":"12","key":"2020122808494592700_pkaa076-B104","doi-asserted-by":"crossref","first-page":"19923","DOI":"10.18632\/oncotarget.15252","article-title":"Does dual HER-2 blockade treatment increase the risk of severe toxicities of special interests in breast cancer patients: a meta-analysis of randomized controlled trials","volume":"8","author":"Hao","year":"2017","journal-title":"Oncotarget"},{"issue":"6","key":"2020122808494592700_pkaa076-B105","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1179\/1973947815Y.0000000025","article-title":"Severe and fatal adverse events risk associated with rituximab addition to B-cell non-Hodgkin\u2019s lymphoma (B-NHL) chemotherapy: a meta-analysis","volume":"27","author":"Hua","year":"2015","journal-title":"J Chemother"},{"issue":"14","key":"2020122808494592700_pkaa076-B106","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1016\/j.ejca.2015.06.106","article-title":"The incidence and relative risk of cardiovascular toxicity in patients treated with new hormonal agents for castration-resistant prostate cancer","volume":"51","author":"Iacovelli","year":"2015","journal-title":"Eur J Cancer"},{"issue":"3","key":"2020122808494592700_pkaa076-B107","doi-asserted-by":"crossref","first-page":"e645","DOI":"10.1016\/j.clgc.2017.12.007","article-title":"The cardiovascular toxicity of abiraterone and enzalutamide in prostate cancer","volume":"16","author":"Iacovelli","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"2020122808494592700_pkaa076-B108","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2147\/TCRM.S191022","article-title":"Risk and incidence of fatal adverse events associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"15","author":"Jiang","year":"2019","journal-title":"Ther Clin Risk Manag"},{"issue":"12","key":"2020122808494592700_pkaa076-B109","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1093\/jjco\/hyy138","article-title":"Combination of transarterial chemoembolization and sorafenib improves outcomes of unresectable hepatocellular carcinoma: an updated systematic review and meta-analysis","volume":"48","author":"Jin","year":"2018","journal-title":"Jpn J Clin Oncol"},{"issue":"4","key":"2020122808494592700_pkaa076-B110","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/leu.2010.313","article-title":"Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and\/or transplant ineligible patients with multiple myeloma: a meta-analysis [Erratum in: Leukemia. 2011;25(9):1523-4]","volume":"25","author":"Kapoor","year":"2011","journal-title":"Leukemia"},{"issue":"3","key":"2020122808494592700_pkaa076-B111","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/annonc\/mdw673","article-title":"Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials","volume":"28","author":"Khosrow-Khavar","year":"2017","journal-title":"Ann Oncol"},{"issue":"1","key":"2020122808494592700_pkaa076-B112","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/ajh.21904","article-title":"Thalidomide versus bortezomib based regimens as first-line therapy for patients with multiple myeloma: a systematic review","volume":"86","author":"Kumar","year":"2011","journal-title":"Am J Hematol"},{"issue":"1","key":"2020122808494592700_pkaa076-B113","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/s10637-009-9310-0","article-title":"Bevacizumab for salvage treatment of metastatic breast cancer: a systemic review and meta-analysis of randomized controlled trials","volume":"29","author":"Lee","year":"2011","journal-title":"Invest New Drugs"},{"issue":"11","key":"2020122808494592700_pkaa076-B114","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1517\/14740338.2015.1089231","article-title":"Trastuzumab-induced cardiotoxicity in elderly women with HER-2-positive breast cancer: a meta-analysis of real-world data","volume":"14","author":"Leung","year":"2015","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"2020122808494592700_pkaa076-B115","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/annonc\/mdt566","article-title":"Effect of adding gemtuzumab ozogamicin to induction chemotherapy for newly diagnosed acute myeloid leukemia: a meta-analysis of prospective randomized phase III trials","volume":"25","author":"Li","year":"2014","journal-title":"Ann Oncol"},{"issue":"9","key":"2020122808494592700_pkaa076-B116","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s12094-015-1293-z","article-title":"Addition of bevacizumab to chemotherapy in patients with ovarian cancer: a systematic review and meta-analysis of randomized trials","volume":"17","author":"Li","year":"2015","journal-title":"Clin Transl Oncol"},{"issue":"1","key":"2020122808494592700_pkaa076-B117","doi-asserted-by":"crossref","first-page":"15746","DOI":"10.1038\/srep15746","article-title":"Efficacy and safety of bevacizumab combined with chemotherapy for managing metastatic breast cancer: a meta-analysis of randomized controlled trials","volume":"5","author":"Li","year":"2015","journal-title":"Sci Rep"},{"issue":"1","key":"2020122808494592700_pkaa076-B118","doi-asserted-by":"crossref","first-page":"14698","DOI":"10.1038\/srep14698","article-title":"Risk of adverse vascular events in newly diagnosed glioblastoma multiforme patients treated with bevacizumab: a systematic review and meta-analysis","volume":"5","author":"Li","year":"2015","journal-title":"Sci Rep"},{"issue":"12","key":"2020122808494592700_pkaa076-B119","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s40261-018-0709-2","article-title":"Cardiovascular toxicities with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a meta-analysis of 77 randomized controlled trials","volume":"38","author":"Li","year":"2018","journal-title":"Clin Drug Investig"},{"issue":"8","key":"2020122808494592700_pkaa076-B120","doi-asserted-by":"crossref","first-page":"5010","DOI":"10.21037\/jtd.2018.07.09","article-title":"Incidence and risk of thromboembolism associated with bevacizumab in patients with non-small cell lung carcinoma","volume":"10","author":"Li","year":"2018","journal-title":"J Thorac Dis"},{"issue":"1","key":"2020122808494592700_pkaa076-B121","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1524-4741.2010.01034.x","article-title":"A meta-analysis of randomized controlled trials comparing chemotherapy plus trastuzumab with chemotherapy alone in HER-2-positive advanced breast cancer","volume":"17","author":"Liao","year":"2011","journal-title":"Breast J"},{"issue":"8","key":"2020122808494592700_pkaa076-B122","doi-asserted-by":"crossref","first-page":"e22681","DOI":"10.1371\/journal.pone.0022681","article-title":"Addition of bevacizumab to chemotherapy in advanced non-small cell lung cancer: a systematic review and meta-analysis","volume":"6","author":"Lima","year":"2011","journal-title":"PLoS One"},{"issue":"1","key":"2020122808494592700_pkaa076-B123","first-page":"39","article-title":"The efficacy and safety of thalidomide-based therapy in patients with advanced non-small cell lung cancer: a meta-analysis","volume":"1","author":"Liu","year":"2014","journal-title":"Contemp Oncol"},{"issue":"41","key":"2020122808494592700_pkaa076-B124","doi-asserted-by":"crossref","first-page":"67661","DOI":"10.18632\/oncotarget.11813","article-title":"Incidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patients","volume":"7","author":"Liu","year":"2016","journal-title":"Oncotarget"},{"issue":"3","key":"2020122808494592700_pkaa076-B125","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00280-017-3386-6","article-title":"Risk of venous and arterial thromboembolic events associated with VEGFR-TKIs: a meta-analysis","volume":"80","author":"Liu","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"issue":"7","key":"2020122808494592700_pkaa076-B126","first-page":"101042831771489","article-title":"Risk of severe pulmonary embolism in cancer patients receiving bevacizumab: results from a meta-analysis of published and unpublished data","volume":"39","author":"Liu","year":"2017","journal-title":"Tumour Biol"},{"issue":"7","key":"2020122808494592700_pkaa076-B127","first-page":"501","article-title":"The efficacy of additional bevacizumab to cytotoxic chemotherapy regimens for the treatment of colorectal cancer: an updated meta-analysis for randomized trials","volume":"28","author":"Lv","year":"2013","journal-title":"Cancer Biother Radio"},{"issue":"3","key":"2020122808494592700_pkaa076-B128","doi-asserted-by":"crossref","first-page":"320","DOI":"10.4103\/0366-6999.174497","article-title":"Thalidomide-based regimens for elderly and\/or transplant ineligible patients with multiple myeloma: a meta-analysis","volume":"129","author":"Lyu","year":"2016","journal-title":"Chin Med J"},{"issue":"1","key":"2020122808494592700_pkaa076-B129","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-12-89","article-title":"Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups","volume":"12","author":"Macedo","year":"2012","journal-title":"BMC Cancer"},{"issue":"10","key":"2020122808494592700_pkaa076-B130","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1002\/ijc.30280","article-title":"Systematic review and meta-analysis of the risk of severe and life-threatening thromboembolism in cancer patients receiving anti-EGFR monoclonal antibodies (cetuximab or panitumumab)","volume":"139","author":"Miroddi","year":"2016","journal-title":"Int J Cancer"},{"key":"2020122808494592700_pkaa076-B131","first-page":"CD006243","article-title":"Trastuzumab containing regimens for early breast cancer","volume":"4","author":"Moja","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"19","key":"2020122808494592700_pkaa076-B132","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1001\/jama.2008.656","article-title":"Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis","volume":"300","author":"Nalluri","year":"2008","journal-title":"JAMA"},{"issue":"2","key":"2020122808494592700_pkaa076-B133","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.lungcan.2013.11.006","article-title":"Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer","volume":"83","author":"Pujol","year":"2014","journal-title":"Lung Cancer"},{"issue":"12","key":"2020122808494592700_pkaa076-B134","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1002\/ijc.27979","article-title":"Risk of venous thromboembolic events associated with VEGFR-TKIs: a systematic review and meta-analysis","volume":"132","author":"Qi","year":"2013","journal-title":"Int J Cancer"},{"issue":"10","key":"2020122808494592700_pkaa076-B135","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s40261-014-0222-1","article-title":"Bevacizumab increases the risk of severe congestive heart failure in cancer patients: an up-to-date meta-analysis with a focus on different subgroups","volume":"34","author":"Qi","year":"2014","journal-title":"Clin Drug Investig"},{"issue":"2","key":"2020122808494592700_pkaa076-B136","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.critrevonc.2014.04.004","article-title":"Risk of arterial thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: an up-to-date meta-analysis","volume":"92","author":"Qi","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"2020122808494592700_pkaa076-B137","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/bcp.12387","article-title":"Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta-analysis of 36 clinical trials","volume":"78","author":"Qi","year":"2014","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"2020122808494592700_pkaa076-B138","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s40261-014-0174-5","article-title":"Risk of hypertension in cancer patients treated with aflibercept: a systematic review and meta-analysis","volume":"34","author":"Qi","year":"2014","journal-title":"Clin Drug Investig"},{"issue":"16","key":"2020122808494592700_pkaa076-B139","doi-asserted-by":"crossref","first-page":"5072","DOI":"10.3748\/wjg.v21.i16.5072","article-title":"Value of bevacizumab in treatment of colorectal cancer: a meta-analysis","volume":"21","author":"Qu","year":"2015","journal-title":"World J Gastroenterol"},{"issue":"3","key":"2020122808494592700_pkaa076-B140","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3109\/02841860903524396","article-title":"Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials","volume":"49","author":"Ranpura","year":"2010","journal-title":"Acta Oncol"},{"issue":"5","key":"2020122808494592700_pkaa076-B141","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/ajh.2010.25","article-title":"Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis","volume":"23","author":"Ranpura","year":"2010","journal-title":"Am J Hypertens"},{"issue":"5","key":"2020122808494592700_pkaa076-B142","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1001\/jama.2011.51","article-title":"Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis","volume":"305","author":"Ranpura","year":"2011","journal-title":"JAMA"},{"key":"2020122808494592700_pkaa076-B143","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/417673","article-title":"Bevacizumab and breast cancer: a meta-analysis of first-line phase III studies and a critical reappraisal of available evidence","volume":"2012","author":"Rossari","year":"2012","journal-title":"J Oncol"},{"key":"2020122808494592700_pkaa076-B144","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.critrevonc.2016.02.013","article-title":"Incidence and relative risk of adverse events of special interest in patients with castration resistant prostate cancer treated with CYP-17 inhibitors: a meta-analysis of published trials","volume":"101","author":"Roviello","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"2020122808494592700_pkaa076-B145","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1007\/s10637-017-0452-1","article-title":"Risk of hypertension with ramucirumab-based therapy in solid tumors: data from a literature based meta-analysis","volume":"35","author":"Roviello","year":"2017","journal-title":"Invest New Drugs"},{"key":"2020122808494592700_pkaa076-B146","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejca.2017.07.003","article-title":"Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis","volume":"84","author":"Rydzewska","year":"2017","journal-title":"Eur J Cancer"},{"key":"2020122808494592700_pkaa076-B147","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ctrv.2017.07.006","article-title":"Incidence and risk of cardiotoxicity in cancer patients treated with targeted therapies","volume":"59","author":"Santoni","year":"2017","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"2020122808494592700_pkaa076-B148","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1093\/annonc\/mdq587","article-title":"Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes","volume":"22","author":"Schutz","year":"2011","journal-title":"Ann Oncol"},{"issue":"4","key":"2020122808494592700_pkaa076-B149","article-title":"Bortezomib for the treatment of multiple myeloma","volume":"2016","author":"Scott","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"2020122808494592700_pkaa076-B150","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1097\/MCG.0b013e3182a87cfd","article-title":"A systematic review of sorafenib in child-pugh A patients with unresectable hepatocellular carcinoma","volume":"47","author":"Shen","year":"2013","journal-title":"J Clin Gastroenterol"},{"issue":"1","key":"2020122808494592700_pkaa076-B151","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1093\/annonc\/mds590","article-title":"Systematic review and meta-analysis of randomised, phase II\/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer","volume":"24","author":"Soria","year":"2013","journal-title":"Ann Oncol"},{"issue":"2","key":"2020122808494592700_pkaa076-B152","doi-asserted-by":"crossref","DOI":"10.1007\/s12032-014-0473-y","article-title":"Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of non-small cell lung cancer: a systematic review and meta-analysis","volume":"32","author":"Sun","year":"2015","journal-title":"Med Oncol"},{"issue":"3","key":"2020122808494592700_pkaa076-B153","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.3892\/ol.2015.2848","article-title":"Lapatinib combined with neoadjuvant paclitaxel-trastuzumab-based chemotherapy in patients with human epidermal growth factor receptor 2-positive breast cancer: a meta-analysis of randomized controlled trials","volume":"9","author":"Sun","year":"2015","journal-title":"Oncol Lett"},{"issue":"10","key":"2020122808494592700_pkaa076-B154","doi-asserted-by":"crossref","first-page":"10409","DOI":"10.1007\/s13277-014-2354-6","article-title":"Risk\/benefit profile of panitumumab-based therapy in patients with metastatic colorectal cancer: evidence from five randomized controlled trials","volume":"35","author":"Tang","year":"2014","journal-title":"Tumor Biol"},{"issue":"7","key":"2020122808494592700_pkaa076-B155","doi-asserted-by":"crossref","first-page":"e67929","DOI":"10.1371\/journal.pone.0067929","article-title":"Efficacy and safety profile of combining vandetanib with chemotherapy in patients with advanced non-small cell lung cancer: a meta-analysis","volume":"8","author":"Tian","year":"2013","journal-title":"PLoS One"},{"issue":"8","key":"2020122808494592700_pkaa076-B156","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1161\/JAHA.117.006278","article-title":"Cardiovascular adverse events in patients with cancer treated with bevacizumab: a meta-analysis of more than 20 000 patients","volume":"6","author":"Totzeck","year":"2017","journal-title":"J Am Heart Assoc"},{"issue":"5","key":"2020122808494592700_pkaa076-B157","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1177\/2047487318755193","article-title":"Cardiovascular diseases in patients receiving small molecules with anti-vascular endothelial growth factor activity: a meta-analysis of approximately 29,000 cancer patients","volume":"25","author":"Totzeck","year":"2018","journal-title":"Eur J Prev Cardiol"},{"issue":"6","key":"2020122808494592700_pkaa076-B158","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.breast.2011.06.009","article-title":"Trastuzumab combined to neoadjuvant chemotherapy in patients with HER2-positive breast cancer: a systematic review and meta-analysis","volume":"20","author":"Valachis","year":"2011","journal-title":"Breast"},{"issue":"9","key":"2020122808494592700_pkaa076-B159","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1002\/ijc.28234","article-title":"Cardiac toxicity in breast cancer patients treated with dual HER2 blockade","volume":"133","author":"Valachis","year":"2013","journal-title":"Int J Cancer"},{"issue":"1","key":"2020122808494592700_pkaa076-B160","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-7-153","article-title":"Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials","volume":"7","author":"Viani","year":"2007","journal-title":"BMC Cancer"},{"key":"2020122808494592700_pkaa076-B161","first-page":"CD005392","article-title":"Anti-angiogenic therapies for metastatic colorectal cancer","volume":"3","author":"Wagner","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"2020122808494592700_pkaa076-B162","first-page":"CD008941","article-title":"Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer","author":"Wagner","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"14","key":"2020122808494592700_pkaa076-B163","doi-asserted-by":"crossref","first-page":"5691","DOI":"10.7314\/APJCP.2014.15.14.5691","article-title":"Efficacy and safety of sorafenib for advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials","volume":"15","author":"Wang","year":"2014","journal-title":"Asian Pac J Cancer Prev"},{"issue":"7","key":"2020122808494592700_pkaa076-B164","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.4103\/0019-509X.154084","article-title":"A meta-analysis of bevacizumab combined with chemotherapy in the treatment of ovarian cancer","volume":"51","author":"Wang","year":"2014","journal-title":"Indian J Cancer"},{"key":"2020122808494592700_pkaa076-B165","first-page":"1","article-title":"Efficacy and safety of novel agent-based therapies for multiple myeloma: a meta-analysis","volume":"2016","author":"Wang","year":"2016","journal-title":"Biomed Res Int"},{"issue":"1","key":"2020122808494592700_pkaa076-B166","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s40261-015-0355-x","article-title":"The impact of ramucirumab on survival in patients with advanced solid tumors: a systematic review and meta-analysis of randomized ii\/iii controlled trials","volume":"36","author":"Wang","year":"2016","journal-title":"Clin Drug Investig"},{"issue":"6","key":"2020122808494592700_pkaa076-B167","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1177\/1060028019895783","article-title":"Comparative toxicities of neoadjuvant chemotherapy with or without bevacizumab in HER2-negative breast cancer patients: a meta-analysis","volume":"54","author":"Wang","year":"2020","journal-title":"Ann Pharmacother"},{"issue":"6","key":"2020122808494592700_pkaa076-B168","doi-asserted-by":"crossref","first-page":"10703","DOI":"10.18632\/oncotarget.12926","article-title":"Bevacizumab combined with chemotherapy for ovarian cancer: an updated systematic review and meta-analysis of randomized controlled trials","volume":"8","author":"Wu","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"2020122808494592700_pkaa076-B169","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1016\/j.clon.2012.09.005","article-title":"Chemotherapy plus vandetanib or chemotherapy alone in advanced non-small cell lung cancer: a meta-analysis of four randomised controlled trials","volume":"25","author":"Xiao","year":"2013","journal-title":"Clin Oncol"},{"issue":"5","key":"2020122808494592700_pkaa076-B170","doi-asserted-by":"crossref","first-page":"e64354","DOI":"10.1371\/journal.pone.0064354","article-title":"Lenalidomide treatment for multiple myeloma: systematic review and meta-analysis of randomized controlled trials","volume":"8","author":"Yang","year":"2013","journal-title":"PLoS One"},{"issue":"10","key":"2020122808494592700_pkaa076-B171","doi-asserted-by":"crossref","first-page":"6575","DOI":"10.1007\/s11033-014-3541-7","article-title":"Transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis","volume":"41","author":"Yang","year":"2014","journal-title":"Mol Biol Rep"},{"issue":"3","key":"2020122808494592700_pkaa076-B172","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s00404-013-2820-1","article-title":"Bevacizumab in the treatment of ovarian cancer: a meta-analysis from four phase III randomized controlled trials","volume":"288","author":"Ye","year":"2013","journal-title":"Arch Gynecol Obstet"},{"issue":"2","key":"2020122808494592700_pkaa076-B173","doi-asserted-by":"crossref","first-page":"e30353","DOI":"10.1371\/journal.pone.0030353","article-title":"Incidence and risk of QTc interval prolongation among cancer patients treated with vandetanib: a systematic review and meta-analysis","volume":"7","author":"Zang","year":"2012","journal-title":"PLoS One"},{"issue":"7","key":"2020122808494592700_pkaa076-B174","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s00277-013-1711-7","article-title":"Bortezomib for patients with previously untreated multiple myeloma: a systematic review and meta-analysis of randomized controlled trials","volume":"92","author":"Zeng","year":"2013","journal-title":"Ann Hematol"},{"issue":"3","key":"2020122808494592700_pkaa076-B175","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/CAD.0b013e3283350e26","article-title":"Sorafenib improves the survival of patients with advanced hepatocellular carcinoma: a meta-analysis of randomized trials","volume":"21","author":"Zhang","year":"2010","journal-title":"Anticancer Drugs"},{"issue":"11","key":"2020122808494592700_pkaa076-B176","first-page":"2857","article-title":"Efficacy and safety of vandetanib, a dual VEGFR and EGFR inhibitor, in advanced non-small-cell lung cancer: a systematic review and meta-analysis","volume":"12","author":"Zhang","year":"2011","journal-title":"Asian Pac J Cancer Prev"},{"issue":"3","key":"2020122808494592700_pkaa076-B177","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1179\/1973947813Y.0000000070","article-title":"Treatment related severe and fatal adverse events with cetuximab in colorectal cancer patients: a meta-analysis","volume":"25","author":"Zhang","year":"2013","journal-title":"J Chemother"},{"issue":"31","key":"2020122808494592700_pkaa076-B178","doi-asserted-by":"crossref","first-page":"51492","DOI":"10.18632\/oncotarget.18190","article-title":"Bevacizumab significantly increases the risks of hypertension and proteinuria in cancer patients: a systematic review and comprehensive meta-analysis","volume":"8","author":"Zhao","year":"2017","journal-title":"Oncotarget"},{"issue":"12","key":"2020122808494592700_pkaa076-B179","doi-asserted-by":"crossref","first-page":"e81858","DOI":"10.1371\/journal.pone.0081858","article-title":"Phase III trials of standard chemotherapy with or without bevacizumab for ovarian cancer: a meta-analysis","volume":"8","author":"Zhou","year":"2013","journal-title":"PLoS One"},{"issue":"3","key":"2020122808494592700_pkaa076-B180","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.7314\/APJCP.2014.15.3.1313","article-title":"Abiraterone for treatment of metastatic castration-resistant prostate cancer: a systematic review and meta-analysis","volume":"15","author":"Zhou","year":"2014","journal-title":"Asian Pac J Cancer Prev"},{"issue":"2","key":"2020122808494592700_pkaa076-B181","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1053\/j.ajkd.2006.11.039","article-title":"Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis","volume":"49","author":"Zhu","year":"2007","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"2020122808494592700_pkaa076-B182","doi-asserted-by":"crossref","first-page":"7111","DOI":"10.7314\/APJCP.2013.14.12.7111","article-title":"Efficacy and safety of Trastuzumab added to standard treatments for HER2-positive metastatic breast cancer patients","volume":"14","author":"Zhu","year":"2013","journal-title":"Asian Pac J Cancer Prev"},{"issue":"9","key":"2020122808494592700_pkaa076-B183","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1080\/07357907.2019.1670203","article-title":"Increased risk of hypertension with enzalutamide in prostate cancer: a meta-analysis","volume":"37","author":"Zhu","year":"2019","journal-title":"Cancer Investig"},{"issue":"69","key":"2020122808494592700_pkaa076-B184","doi-asserted-by":"crossref","first-page":"113318","DOI":"10.18632\/oncotarget.22966","article-title":"Evaluation of efficacy and safety for bevacizumab in treating malignant pleural effusions caused by lung cancer through intrapleural injection","volume":"8","author":"Zongwen","year":"2017","journal-title":"Oncotarget"},{"issue":"9","key":"2020122808494592700_pkaa076-B185","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.3109\/10428194.2013.847935","article-title":"Bortezomib and lenalidomide as front-line therapy for multiple myeloma","volume":"55","author":"Zou","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"2020122808494592700_pkaa076-B186","doi-asserted-by":"crossref","first-page":"e102484","DOI":"10.1371\/journal.pone.0102484","article-title":"Increased risk of cerebrovascular events in patients with cancer treated with bevacizumab: a meta-analysis","volume":"9","author":"Zuo","year":"2014","journal-title":"PLoS One"},{"issue":"5","key":"2020122808494592700_pkaa076-B187","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1517\/14740338.2013.788642","article-title":"Cardiovascular toxicity of tyrosine kinase inhibitors","volume":"12","author":"Mouhayar","year":"2013","journal-title":"Expert Opin Drug Saf"},{"issue":"6","key":"2020122808494592700_pkaa076-B188","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s40264-013-0050-x","article-title":"Tyrosine kinase inhibitors: their on-target toxicities as potential indicators of efficacy","volume":"36","author":"Shah","year":"2013","journal-title":"Drug Saf"},{"issue":"1","key":"2020122808494592700_pkaa076-B189","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12885-019-5280-6","article-title":"Abiraterone acetate plus prednisone for the management of metastatic castration-resistant prostate cancer (mCRPC) without prior use of chemotherapy: report from a large, international, real-world retrospective cohort study","volume":"19","author":"Boegemann","year":"2019","journal-title":"BMC Cancer"},{"issue":"6","key":"2020122808494592700_pkaa076-B190","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1080\/17460441.2018.1455662","article-title":"Current and potential targets for drug design in the androgen receptor pathway for prostate cancer","volume":"13","author":"Guddati","year":"2018","journal-title":"Expert Opin Drug Discov"},{"issue":"4","key":"2020122808494592700_pkaa076-B191","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/1758834016642370","article-title":"CYP17 inhibitors in prostate cancer: latest evidence and clinical potential","volume":"8","author":"Alex","year":"2016","journal-title":"Ther Adv Med Oncol"},{"issue":"3","key":"2020122808494592700_pkaa076-B192","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.eururo.2014.11.039","article-title":"Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis","volume":"68","author":"Bosco","year":"2015","journal-title":"Eur Urol"},{"issue":"3","key":"2020122808494592700_pkaa076-B193","doi-asserted-by":"crossref","first-page":"e0117344","DOI":"10.1371\/journal.pone.0117344","article-title":"Quantifying the evidence for the risk of metabolic syndrome and its components following androgen deprivation therapy for prostate cancer: a meta-analysis","volume":"10","author":"Bosco","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"2020122808494592700_pkaa076-B194","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1517\/14740338.2015.986092","article-title":"Conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy","volume":"14","author":"Bronte","year":"2015","journal-title":"Expert Opin Drug Saf"},{"issue":"20","key":"2020122808494592700_pkaa076-B195","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1093\/jnci\/86.20.1534","article-title":"Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment","volume":"86","author":"Love","year":"1994","journal-title":"J Natl Cancer Inst"},{"issue":"6847","key":"2020122808494592700_pkaa076-B196","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1136\/bmj.305.6847.225","article-title":"Long term effects of tamoxifen on blood lipid values in breast cancer","volume":"305","author":"Dewar","year":"1992","journal-title":"BMJ"},{"key":"2020122808494592700_pkaa076-B197","doi-asserted-by":"crossref","first-page":"k3845","DOI":"10.1136\/bmj.k3845","article-title":"Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: systematic review","volume":"363","author":"Matthews","year":"2018","journal-title":"BMJ"},{"issue":"1","key":"2020122808494592700_pkaa076-B198","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s12185-018-2540-1","article-title":"Venous thromboembolism in relapsed or refractory multiple myeloma patients treated with lenalidomide plus dexamethasone","volume":"109","author":"Shin","year":"2019","journal-title":"Int J Hematol"},{"issue":"2","key":"2020122808494592700_pkaa076-B199","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.leu.2405062","article-title":"Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma","volume":"22","author":"Palumbo","year":"2008","journal-title":"Leukemia"},{"issue":"9","key":"2020122808494592700_pkaa076-B200","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nrcardio.2015.65","article-title":"Cardiotoxicity of anticancer treatments","volume":"12","author":"Ewer","year":"2015","journal-title":"Nat Rev Cardiol"},{"issue":"3","key":"2020122808494592700_pkaa076-B201","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.tips.2005.01.003","article-title":"Predicting drug-hERG channel interactions that cause acquired long QT syndrome","volume":"26","author":"Sanguinetti","year":"2005","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"2020122808494592700_pkaa076-B202","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41698-017-0034-x","article-title":"Precision cardio-oncology: understanding the cardiotoxicity of cancer therapy","volume":"1","author":"Han","year":"2017","journal-title":"NPJ Precis Oncol"},{"issue":"9","key":"2020122808494592700_pkaa076-B203","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1080\/14740338.2018.1513488","article-title":"Cardiovascular safety of oncologic agents: a double-edged sword even in the era of targeted therapies\u2014part 1","volume":"17","author":"Manolis","year":"2018","journal-title":"Expert Opin Drug Saf"},{"issue":"4","key":"2020122808494592700_pkaa076-B204","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1136\/ebmed-2016-110401","article-title":"New evidence pyramid","volume":"21","author":"Murad","year":"2016","journal-title":"Evid Based Med"},{"issue":"3","key":"2020122808494592700_pkaa076-B205","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/1468-0009.12210","article-title":"The mass production of pedundant, misleading, and conflicted systematic reviews and meta-analyses","volume":"94","author":"Ioannidis","year":"2016","journal-title":"Milbank Q"},{"issue":"12","key":"2020122808494592700_pkaa076-B206","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.jclinepi.2014.08.008","article-title":"Up-to-dateness of reviews is often neglected in overviews: a systematic review","volume":"67","author":"Pieper","year":"2014","journal-title":"J Clin Epidemiol"},{"key":"2020122808494592700_pkaa076-B207","first-page":"MR000030","article-title":"Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals","volume":"11","author":"Turner","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"2020122808494592700_pkaa076-B208","article-title":"Bias due to selective inclusion and reporting of outcomes and analyses in systematic reviews of randomised trials of healthcare interventions","volume":"10","author":"Page","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"2020122808494592700_pkaa076-B209","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1001\/jamaoncol.2019.2564","article-title":"Evaluation of reproducible research practices in oncology systematic reviews with meta-analyses referenced by national comprehensive cancer network guidelines","volume":"5","author":"Wayant","year":"2019","journal-title":"JAMA Oncol"}],"container-title":["JNCI Cancer Spectrum"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jncics\/advance-article-pdf\/doi\/10.1093\/jncics\/pkaa076\/33678209\/pkaa076.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jncics\/article-pdf\/4\/6\/pkaa076\/35198150\/pkaa076.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jncics\/article-pdf\/4\/6\/pkaa076\/35198150\/pkaa076.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,11]],"date-time":"2024-08-11T22:32:46Z","timestamp":1723415566000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jncics\/article\/doi\/10.1093\/jncics\/pkaa076\/5896537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,24]]},"references-count":209,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,11,15]]}},"URL":"https:\/\/doi.org\/10.1093\/jncics\/pkaa076","relation":{},"ISSN":["2515-5091"],"issn-type":[{"value":"2515-5091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,12]]},"published":{"date-parts":[[2020,8,24]]},"article-number":"pkaa076"}}